肿瘤细胞治疗研究
英文原题：Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies.
CAR-T（CAR T）细胞疗法是一种新的治疗范式，已经彻底改变了CD19阳性B细胞恶性肿瘤和BCMA阳性浆细胞恶性肿瘤的治疗。
CAR-T（CAR T）细胞治疗是一种新的治疗范式，已经彻底改变了CD19阳性B细胞恶性肿瘤和BCMA阳性浆细胞恶性肿瘤的治疗。与历史队列相比，缓解率非常令人印象深刻，但缓解并不持久。关键试验的最新结果表明，当前的CAR T细胞产品未能展示出最佳的长期疾病控制。对CAR T细胞的耐药性与CAR结构、T细胞因素、肿瘤因素和免疫抑制微环境有关。CAR T细胞治疗失败后需要新的策略。在这篇综述中，我们根据疾病讨论了CAR T细胞治疗的耐药机制以及克服耐药的新兴策略。
Chimeric antigen receptor T (CAR T) cell therapy is a new treatment paradigm that has revolutionized the treatment of CD19-positive B cell malignancies and BCMA-positive plasma cell malignancies. The response rates are highly impressive in comparison to historical cohorts, but the responses are not durable. The most recent results from pivotal trials show that current CAR T cell products fail to demonstrate optimal long-term disease control. Resistance to CAR T cells is related to CAR structure, T cell factors, tumor factors and the immunosuppressive microenvironment. Novel strategies are needed following failure with CAR T cell treatment. In this review, we discuss the resistance mechanisms to CAR T cell treatment according to disease and the emerging strategies to overcome resistance.
MEMBER ACCOUNT
登录成功会直接打开下一页。
